TY - STD TI - Treatment with hypoglycemic agents (other than insulin). Evidence-based Practice Guidelines for the Treatment of Diabetes in Japan. Edited by: The Japan Diabetes Society. 2010, Tokyo: Nankodo Co., Ltd, 51-63. ID - ref1 ER - TY - JOUR AU - Inzucchi, S. E. AU - Bergenstal, R. M. AU - Buse, J. B. AU - Diamant, M. AU - Ferrannini, E. AU - Nauck, M. AU - Peters, A. L. AU - Tsapas, A. AU - Wender, R. AU - Matthews, D. R. PY - 2012 DA - 2012// TI - Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) JO - Diabetes Care VL - 35 UR - https://doi.org/10.2337/dc12-0413 DO - 10.2337/dc12-0413 ID - Inzucchi2012 ER - TY - JOUR AU - Misra, M. PY - 2013 DA - 2013// TI - SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus JO - J Pharm Pharmacol VL - 63 UR - https://doi.org/10.1111/j.2042-7158.2012.01574.x DO - 10.1111/j.2042-7158.2012.01574.x ID - Misra2013 ER - TY - BOOK PY - 2010 DA - 2010// TI - Notification No. 0709-1 (July 9, 2010): Guideline for Clinical Evaluation of Oral Hypoglycemic Agents PB - Ministry of Health, Labour and Welfare CY - Tokyo ID - ref4 ER - TY - JOUR AU - Inagaki, N. AU - Kondo, K. AU - Yoshinari, T. AU - Maruyama, N. AU - Susuta, Y. AU - Kuki, H. PY - 2013 DA - 2013// TI - Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study JO - Diabetes Obes Metab VL - 15 UR - https://doi.org/10.1111/dom.12149 DO - 10.1111/dom.12149 ID - Inagaki2013 ER - TY - JOUR AU - Stenlöf, K. AU - Cefalu, W. T. AU - Kim, K. A. AU - Alba, M. AU - Usiskin, K. AU - Tong, C. AU - Canovatchel, W. AU - Meininger, G. PY - 2013 DA - 2013// TI - Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise JO - Diabetes Obes Metab VL - 15 UR - https://doi.org/10.1111/dom.12054 DO - 10.1111/dom.12054 ID - Stenlöf2013 ER - TY - JOUR AU - Bolinder, J. AU - Ljunggren, Ö. AU - Kullberg, J. AU - Johansson, L. AU - Wilding, J. AU - Langkilde, A. M. AU - Sugg, J. AU - Parikh, S. PY - 2012 DA - 2012// TI - Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin JO - J Clin Endocrinol Metab VL - 97 UR - https://doi.org/10.1210/jc.2011-2260 DO - 10.1210/jc.2011-2260 ID - Bolinder2012 ER - TY - JOUR AU - Wilding, J. P. AU - Hardy, K. PY - 2011 DA - 2011// TI - Glucagon-like peptide-1 analogues for type 2 diabetes JO - BMJ VL - 342 UR - https://doi.org/10.1136/bmj.d410 DO - 10.1136/bmj.d410 ID - Wilding2011 ER - TY - JOUR AU - Kaku, K. AU - Inoue, S. AU - Matsuoka, O. AU - Kiyosue, A. AU - Azuma, H. AU - Hayashi, N. AU - Tokudome, T. AU - Langkilde, A. M. AU - Parikh, S. PY - 2013 DA - 2013// TI - Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a Phase II multicentre, randomized, double-blind, placebo-controlled trial JO - Diabetes Obes Metab VL - 5 UR - https://doi.org/10.1111/dom.12047 DO - 10.1111/dom.12047 ID - Kaku2013 ER - TY - CHAP AU - Tanizawa, Y. AU - Kaku, K. AU - Araki, E. AU - Tobe, K. AU - Terauchi, Y. AU - Utsunomiya, K. AU - Iwamoto, Y. AU - Watada, H. AU - Ohtsuka, W. AU - Watanabe, D. AU - Suganami, H. PY - 2014 DA - 2014// TI - Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials BT - Expert Opin Pharmacother ID - Tanizawa2014 ER - TY - JOUR AU - Vasilakou, D. AU - Karagiannis, T. AU - Athanasiadou, E. AU - Mainou, M. AU - Liakos, A. AU - Bekiari, E. AU - Sarigianni, M. AU - Matthews, D. R. AU - Tsapas, A. PY - 2013 DA - 2013// TI - Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis JO - Ann Intern Med VL - 159 UR - https://doi.org/10.7326/0003-4819-159-4-201308200-00007 DO - 10.7326/0003-4819-159-4-201308200-00007 ID - Vasilakou2013 ER - TY - JOUR AU - Wright, E. M. PY - 2001 DA - 2001// TI - Renal Na(+)-glucose cotransporters JO - Am J Physiol Renal Physiol VL - 280 ID - Wright2001 ER - TY - JOUR AU - Chao, E. C. AU - Henry, R. R. PY - 2010 DA - 2010// TI - SGLT2 inhibition—a novel strategy for diabetes treatment JO - Nat Rev Drug Discov VL - 9 UR - https://doi.org/10.1038/nrd3180 DO - 10.1038/nrd3180 ID - Chao2010 ER - TY - JOUR AU - Magen, D. AU - Sprecher, E. AU - Zelikovic, I. AU - Skorecki, K. PY - 2005 DA - 2005// TI - A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria JO - Kidney Int VL - 67 UR - https://doi.org/10.1111/j.1523-1755.2005.00053.x DO - 10.1111/j.1523-1755.2005.00053.x ID - Magen2005 ER - TY - JOUR AU - Kleta, R. AU - Stuart, C. AU - Gill, F. A. AU - Gahl, W. A. PY - 2004 DA - 2004// TI - Renal glucosuria due to SGLT2 mutations JO - Mol Genet Metab VL - 82 UR - https://doi.org/10.1016/j.ymgme.2004.01.018 DO - 10.1016/j.ymgme.2004.01.018 ID - Kleta2004 ER - TY - JOUR AU - Wright, E. M. AU - Turk, E. AU - Martin, M. G. PY - 2002 DA - 2002// TI - Molecular basis for glucose-galactose malabsorption JO - Cell Biochem Biophys VL - 36 UR - https://doi.org/10.1385/CBB:36:2-3:115 DO - 10.1385/CBB:36:2-3:115 ID - Wright2002 ER - TY - JOUR AU - Suzuki, M. AU - Honda, K. AU - Fukazawa, M. AU - Ozawa, K. AU - Hagita, H. AU - Kawai, T. AU - Takeda, M. AU - Yata, T. AU - Kawai, M. AU - Fukuzawa, T. AU - Kobayashi, T. AU - Sato, T. AU - Kawabe, Y. AU - Ikeda, S. PY - 2012 DA - 2012// TI - Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice JO - J Pharmacol Exp Ther VL - 341 UR - https://doi.org/10.1124/jpet.112.191593 DO - 10.1124/jpet.112.191593 ID - Suzuki2012 ER - TY - JOUR AU - Barnett, A. H. PY - 2013 DA - 2013// TI - Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus JO - Postgrad Med VL - 125 UR - https://doi.org/10.3810/pgm.2013.09.2698 DO - 10.3810/pgm.2013.09.2698 ID - Barnett2013 ER - TY - JOUR AU - Ridderstråle, M. AU - Svaerd, R. AU - Zeller, C. AU - Kim, G. AU - Woerle, H. J. AU - Broedl, U. C. PY - 2013 DA - 2013// TI - Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control JO - Cardiovasc Diabetol VL - 12 UR - https://doi.org/10.1186/1475-2840-12-129 DO - 10.1186/1475-2840-12-129 ID - Ridderstråle2013 ER -